Tempus Launches TIME Precision Network to Fast-Track Phase I Clinical Trial Activation and Enrollment

Tempus AI, Inc., a leading technology company in the field of AI-driven precision medicine, announced the expansion of its TIME Network to support Phase I clinical trials. This initiative aims to accelerate the activation and enrollment of these early-stage studies, which are crucial for drug development and offer significant benefits to patients. Since its launch in 2019, the TIME Network has been instrumental in identifying and enrolling patients for clinical trials quickly and efficiently, often within days or weeks. To enhance support for Phase I trials, Tempus has formed the TIME Precision Network, a group of expert investigators spread across more than 40 research centers capable of conducting such trials. The primary focus of this network is to expedite the activation and enrollment processes, ensuring that patients in diverse communities gain access to cutting-edge treatments. Recently, the TIME Network achieved notable milestones by enrolling the first patient in multiple Phase I trials. One of the most significant examples of the network's effectiveness is the Nimbus 9216-101 study at the Taylor Cancer Research Center (TCRC). Tempus managed to activate the site in just two weeks and enrolled the first patient within a month. Similarly, the Pathos P300-02-001 study saw the rapid enrollment of its first and second patients at Nebraska Cancer Specialists and Oncology Consultants, both within weeks of site activation. These achievements highlight the network's capability to streamline processes and reduce the time typically required for such trials. The initiative is led by Tempus' Chief Medical Officer, Oncology, Dr. Ezra Cohen. He emphasized the importance of the TIME Precision Network in adding critical capabilities to the overall TIME Network, stating, "These studies require specific and coordinated infrastructure, and I am proud that Tempus can now work with these sites and our life science partners to enroll patients into these cutting-edge clinical trials." Dr. John Nemunaitis, Chief Scientific Officer at TCRC, also praised the collaboration, noting, "It’s a privilege for us at the TCRC to work with Tempus in engaging new precision trial opportunities for our cancer patients. Our partnership has established a seamless process for study activation and patient enrollment, as evidenced by our recent success with the novel WRN inhibitor by Nimbus." Tempus has been committed to building a robust network of provider sites, including community hospitals that often serve underrepresented patient groups. By integrating these sites, Tempus is breaking down barriers to clinical trial participation, making it easier for patients to access investigational therapies. This expansion not only benefits patients but also enhances the quality and scope of research across various medical institutions. The TIME Network leverages Tempus' vast library of multimodal data and advanced AI capabilities to match patients with appropriate clinical trials and to facilitate the rapid activation of trial sites. This integrated approach ensures that clinical trials can begin and progress quickly, potentially speeding up the development and approval of new treatments. In a broader context, this move by Tempus underscores the growing importance of AI in enhancing the efficiency and accessibility of medical research. Industry insiders applaud the company for its innovative approach, highlighting that such initiatives could lead to faster breakthroughs in treating complex diseases. They note that Tempus' ability to identify and enroll patients rapidly is a game-changer, especially in the realm of precision medicine, where timely access to treatments can significantly impact patient outcomes. Tempus, founded in 2015, is known for its pioneering work in AI for precision medicine. The company's platform includes a comprehensive data library and sophisticated tools that help physicians deliver personalized care. By continuously gathering and analyzing data, Tempus aims to improve therapeutic outcomes and drive forward the development of optimal treatments. For more information, visit tempus.com. Forward-looking statements in this press release should be read with caution, as they are subject to various risks and uncertainties, including but not limited to Tempus' financial performance, market competition, and regulatory compliance. Tempus does not undertake any obligation to update or revise these statements to reflect new information or events.